Medtronic received the first U.S. Food and Drug Administration (FDA) approval for an implantable cardioverter defibrillator (ICD) system for use with magnetic resonance imaging (MRI) scans. The Medtronic Evera MRI SureScan ICD System is approved for MRI scans on any part of the body without positioning restrictions, which means that patients who depend on life-saving ICDs also now have access to MRI scans if and when they need them. The newly approved system, which will be commercially available in September 2015, includes the Evera MRI ICD and Sprint Quattro Secure MRI SureScan DF4 leads, which must be used together to be considered MR-conditional.

Texas Heart Institute, Rice University, grant, nanotubes, heart, electrical signals

Texas Heart Institute (THI) announced that it has received a prestigious American Heart Association grant alongside Rice University. The three-year, $750,000 grant will allow THI and Rice researchers to study and test soft, flexible fibers made of carbon nanotubes. The fibers’ ability to bridge electrical gaps in tissue is a groundbreaking discovery and offers hope to the millions of people affected by cardiac arrhythmias.

Startup cardiovascular device manufacturer Valtech Cardio Ltd. announced it has received CE Marking for its Cardioband mitral reconstruction system (Cardioband), a proprietary, implantable mitral reconstruction device with a transfemoral, transseptal delivery system for mitral valve repair.

Vital Images Inc. recently introduced the VioSuite Image Management and Vitality Solutions Business Intelligence product families, providing healthcare administrators with a robust set of tools to improve system-wide image access and image data analytics. VioSuite and Vitality Solutions, as well as the company’s flagship products VitreaAdvanced and VitreaView software, were showcased at the 9th annual Health Information and Management Systems Society (HIMSS) Asia Pacific Conference and Exhibition.

September 14, 2015 — Healthcare providers can assess a patient’s risk of sudden cardiac death (SCD) following a percutaneous coronary intervention (PCI) using a new point-of-care post-PCI risk calculator available for download at SCDFacts.org and in the iTunes or Android app stores.

The assessment is based on the 10 most clinically relevant SCD mortality risk factors, as identified and supported by numerous peer-reviewed articles and studies.  

New Haven Pharmaceuticals Inc. announced U.S. Food and Drug Administration (FDA) approval of Durlaza (aspirin) 24-hour extended-release capsules for the secondary prevention of stroke and acute cardiac events, including myocardial infarction.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now